🍪 CompoundTalk uses cookies to improve your experience, analyze traffic, and personalize content. By continuing to use this site, you agree to our Cookie Policy.
Evidence-based GLP-1 & peptide discussion since 2023
ForumsInternationalHas anyone dealt with german krankenkasse coverage for glp-1? Page 3

Has anyone dealt with german krankenkasse coverage for glp-1?

MarkLI_maint Wed, Sep 10, 2025 at 12:18 PM 19 replies 1,556 viewsPage 3 of 4
AussieAnna
Member
678
2,890
Jun 2024
Sydney, AU
Sep 13, 2025 at 10:09 AM#11
rachel_ABQ said:
Insurance coverage hack for cost and coverage: if your insurance denies brand Wegovy/Ozempic, consider these alternatives: Prior authorization appeal…

Thank you — that is the clearest version of this I have read, and I have read a lot of them. Printing the relevant bit and taking it with me.

3 3TrialNerd_Beth, HPLC_Greg, LibrarianMeg
Reply Quote Save Share Report
Dr.AddMedPHL
Senior Member
1,234
6,234
Mar 2024
Philadelphia, PA
Sep 14, 2025 at 3:02 PM#12

From the other side of the consultation, briefly.

My insurance denied my PA related to cost and coverage. Has anyone successfully appealed? I'm considering going compounded instead.

2 2sarah_nash92, FitDadDave
Reply Quote Save Share Report
NurseKim_ATL
Senior Member
1,678
7,234
Feb 2024
Atlanta, GA
Sep 15, 2025 at 7:54 PM#13
SarahChen_PharmD said:
Dr.RaviCardio said: ...compounded vs brand cost and coverage...

Financial impact of cost and coverage weight loss beyond medication cost:

  • Groceries: SAVED $250/month (eating less)
  • Restaurants: SAVED $160/month (fewer meals out)
  • Alcohol: SAVED $110/month (stopped drinking)
  • Life insurance: Premium REDUCED by $40/month (lower BMI)
  • Copays: SAVED $60/month (fewer BP/cholesterol meds)

Net impact after medication cost: approximately BREAKING EVEN. The medication pays for itself through reduced food spending and healthcare costs. This surprised me.

1 1ingrid_STO
Reply Quote Save Share Report

PeptideMeter — Independent Peptide Analytics

Community-driven peptide testing and vendor rating platform. Transparent results. Unbiased analysis. Trusted by thousands.

View Results
TrialTracker_MD
Senior Member
2,345
15,678
Jan 2024
Maryland
Sep 17, 2025 at 12:46 AM#14
MarkLI_maint said:
Denials are usually procedural rather than clinical, and the order that works reflects that.
MarkLI_maint said:
...regarding the discontinuation data for cost and coverage...

I want to reframe the discontinuation narrative. We don't say "insulin fails because blood sugar rises when you stop it." We don't say "antihypertensives fail because BP goes up without them."

Why do we apply different logic to anti-obesity medications? The answer is stigma. We still, unconsciously, believe obesity is about willpower rather than biology. The discontinuation data actually PROVES it's a chronic biological condition requiring ongoing treatment.

This reframing isn't semantic — it has implications for insurance coverage, treatment duration, and patient expectations.

50 0Dr.PulmRoch, maya_sedona, stefan_berlin and 47 others
Reply Quote Save Share Report
Admin
Administrator
2,456
9,812
Oct 2023
Online
Sep 18, 2025 at 5:37 AM#15

Moderator note: the sourcing question belongs in the vendor section and has been split out. No action needed from anybody.

49 24PeptideSynthNJ, Dr.KarenChen, Dr.NateNeph and 46 others
Reply Quote Save Share Report

Similar Threads

EU EMA compounding guidance — 2026 regulatory update9 replies
UK NHS GLP-1 prescribing — NICE TA875 and access guide7 replies
Australian TGA scheduling changes — peptide access 20268 replies
Canadian GLP-1 coverage — provincial formulary comparison6 replies
Purchasing GLP-1 in Mexico — legality, quality, and safety concerns6 replies
ForumsNewTrendingMembersAccount

Log In

Forgot password?
No account? Register